Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system
Authors:
- Tetsuzo TauchiTTTetsuzo Tauchi
- Shinichiro OkamotoSOShinichiro Okamoto
- Tohru MurayamaTMTohru Murayama
- Yoshio SaburiYSYoshio Saburi
- Mitsuru TsudoMTMitsuru Tsudo
- Taizo ShimomuraTSTaizo Shimomura
- 1 May 2011
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 35 (5) , 585-590
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaLeukemia, 2009
- Current and future perspectives on the TARGET system: the registration system for Glivec® established by the JSHInternational Journal of Hematology, 2008
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implicationsNature Medicine, 2006
- The Importance of Reporting Patient Recruitment Details in Phase III TrialsJournal of Clinical Oncology, 2006
- Dynamics of chronic myeloid leukaemiaNature, 2005
- Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Clinical Trials: Time for ActionJournal of Clinical Oncology, 2003
- Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitroBlood, 2002